Roivant's Brepocitinib Meets Primary Endpoint in Both Phase 3 NIU Trials
ROIV has more than doubled off its 52-week low of $17.28.
Summary
Roivant and Priovant reported positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib in non-infectious uveitis, with statistically significant benefit on the primary and all key secondary endpoints and an sNDA planned for the first half of 2027.
Key Events · Product Development and Regulatory · ROIV
-
Both Phase 3 NIU Trials Met Primary Endpoint
Across 371 enrolled patients, brepocitinib 45 mg once daily beat placebo on time to treatment failure in CLARITY-1 (HR 0.27, 95% CI 0.17-0.43) and CLARITY-2 (HR 0.22, 95% CI 0.14-0.34), both p<0.0001.
-
Large Effect on Steroid-Free Disease Control
Median time to treatment failure exceeded 48 weeks on brepocitinib versus about 12 weeks on placebo. Pooled across studies, 62% of treated patients achieved steroid-free quiescence at Week 48 versus 20% on placebo (p<0.0001).
-
Macular Edema Resolution Far Above Placebo
Among eyes with baseline macular edema, 42% on brepocitinib resolved at Week 48 versus 4.8% on placebo (p<0.0001), a key driver of vision loss in NIU.
-
Safety Consistent With Prior Trials
Most adverse events were mild or moderate, only 3% of participants discontinued for an adverse event, and no new safety findings were observed.
Analysis · ROIV · Life Sciences
Brepocitinib came through both identical Phase 3 CLARITY studies in non-infectious uveitis, a disease that has gone roughly a decade without a new systemic non-steroid option. The effect size is large: median time to treatment failure exceeded 48 weeks versus about 12 weeks on placebo, and 62% of treated patients reached steroid-free quiescence at Week 48 versus 20% on placebo. That points to a second commercial indication for a drug Roivant already sells as LISRAYA for dermatomyositis, with an sNDA planned for the first half of 2027. The main risk here is timing and regulatory execution, not the data, which showed no new safety findings.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.80%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $36.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $17.28 to $42.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.